As mentioned in AML, the FB23 and FB23-2 (the inhibitors of FTO), which are designed based on the molecular structure of the protein of FTO, increase the level of m6A methylation, inhibit the proliferation of cell lines in vitro, and have a significant anti-leukemia therapeutic effect on patient-derived xenograft mouse models (92). This evidence concerns the gene FTO and acute myeloid leukemia.